Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：6
|
作者：
Shah, Jatin J. [1 ]
Feng, Lei [2 ]
Thomas, Sheeba K. [3 ]
Weber, Donna [3 ]
Wang, Michael [4 ]
Manasanch, Elisabet E. [3 ]
Mendoza, Kathleen [3 ]
Orlowski, Robert Z. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.1540.1540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [32] Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)
    Orlowski, Robert Z.
    Zaman, Shadia
    Thomas, Sheeba K.
    Alexanian, Raymond
    Shah, Jatin J.
    Weber, Donna M.
    Wang, Michael
    Holloway, Ashley N.
    Baladandayuthapani, Veerabhadran
    Lin, Heather Yan
    Fu, Min
    Stellrecht, Christine M.
    de Partovi, Claudia Morales
    Gandhi, Varsha
    BLOOD, 2013, 122 (21)
  • [33] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [34] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Juan Du
    Baijun Fang
    Jian Li
    Jie Jin
    Shunqing Wang
    Dehui Zou
    Zhen Cai
    Hongxiang Wang
    Jianda Hu
    Wei Li
    Chengcheng Fu
    Zonghong Shao
    Zhongjun Xia
    Peng Liu
    Ting Niu
    En-Tzu Tang
    Amy S. Kimball
    Jian Hou
    Wenming Chen
    International Journal of Hematology, 2021, 113 : 422 - 429
  • [35] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy S.
    Hou, Jian
    Chen, Wenming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
  • [36] A Phase 1 Dose-Escalation Study of Filanesib Plus Bortezomib and Dexamethasone in Patients With Recurrent/ Refractory Multiple Myeloma
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey A.
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Levy, Joan B.
    Lau, Kenneth
    Burt, Steven M.
    Tunquist, Brian J.
    Hilder, Brandi W.
    Rush, Selena A.
    Walker, Duncan H.
    Ptaszynski, Mieke
    Kaufman, Jonathan L.
    CANCER, 2016, 122 (21) : 3327 - 3335
  • [37] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    De Novellis, Danilo
    Derudas, Daniele
    Vincelli, Donatella
    Fontana, Raffaele
    Della Pepa, Roberta
    Palmieri, Salvatore
    Accardi, Fabrizio
    Rotondo, Francesco
    Morelli, Emanuela
    Gigliotta, Emilia
    Roccotelli, Daniela
    Marano, Luana
    Barone, Maria Lucia
    Cetani, Giusy
    Esposito, Daniela
    Lazzaro, Antonio
    Delle Cave, Giuseppe
    Serio, Bianca
    Morini, Denise
    Porrazzo, Marika
    Urciuoli, Eleonora
    Masucci, Chiara
    Fanelli, Fulvia
    Rizzo, Michela
    Arcamone, Manuela
    Trastulli, Fabio
    Rocco, Stefano
    Leone, Aldo
    Bianco, Rosario
    Salvatore, Flavia
    Idato, Aurora
    Sicari, Maria
    Tosi, Patrizia
    Rascato, Maria Gabriella
    Di Perna, Maria
    Falcone, Antonietta Pia
    Morello, Lucia
    Carlisi, Melania
    Svanera, Gino
    Annunziata, Mario
    Frigeri, Ferdinando
    Califano, Catello
    Carella, Angelo Michele
    Marcacci, Gianpaolo
    Pane, Fabrizio
    Risitano, Antonio Maria
    Giudice, Valentina
    Botta, Ciro
    Selleri, Carmine
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
  • [38] Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
    Rowinsky, Eric K.
    Paner, Agne
    Berdeja, Jesus G.
    Paba-Prada, Claudia
    Venugopal, Parameswaran
    Porkka, Kimmo
    Gullbo, Joachim
    Linder, Stig
    Loskog, Angelica
    Richardson, Paul G.
    Landgren, Ola
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1448 - 1453
  • [39] Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
    Eric K. Rowinsky
    Agne Paner
    Jesus G. Berdeja
    Claudia Paba-Prada
    Parameswaran Venugopal
    Kimmo Porkka
    Joachim Gullbo
    Stig Linder
    Angelica Loskog
    Paul G. Richardson
    Ola Landgren
    Investigational New Drugs, 2020, 38 : 1448 - 1453
  • [40] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
    Berdeja, Jesus G.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Essell, James H.
    Owera, Rami S.
    Hainsworth, John D.
    Flinn, Ian W.
    HAEMATOLOGICA, 2015, 100 (05) : 670 - 676
12345